News Related to NovaBridge Biosciences

Related coverage linked through entity extraction aliases.

ABL111 gains FDA accelerated approval pathway as phase 2 gastric cancer trial begins

May 13, 2026

ABL111 received FDA agreement on an accelerated approval pathway for metastatic gastric cancer as the first patient was dosed in a global phase 2 trial. The companies said ORR will support accelerated approval and phase 2 is evaluating ABL111 with nivolumab and mFOLFOX6.

NovaBridge Enrolls First Patient in Phase 2 Study of Givastomig for Gastric Cancer

Feb 18, 2026

NovaBridge Biosciences has enrolled the first patient in a global Phase 2 study evaluating givastomig in combination with nivolumab and chemotherapy for HER2-negative, first-line metastatic gastric cancer, with top-line results expected in 2027.